Albumin activates the canonical TGF receptor-smad signaling pathway but this is not required for activation of astrocytes

Experimental Neurology

Volumn 226, Issue 2, 2010, Pages 310-319

  Ranaivo, Hantamalala Ralay ^a   Patel, Fatima ^a   Wainwright, Mark S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Albumin; Astrocyte; Cytokines; Smads; TGF receptor

Indexed keywords

ALBUMIN; FRACTALKINE; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; PROTEIN S100B; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION;

ALBUMINS; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BENZAMIDES; CELLS, CULTURED; CEREBRAL CORTEX; CHEMOKINE CXCL1; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN-1BETA; L-LACTATE DEHYDROGENASE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRITES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 77958492335     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.09.005     Document Type: Article

References (50)

1. Allan S.M., Tyrrell P.J., Rothwell N.J. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 2005, 5:629-640.
2. Balosso S., Maroso M., Sanchez-Alavez M., Ravizza T., Frasca A., Bartfai T., Vezzani A. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1β. Brain 2008, 131:3256-3265.
3. Belayev L., Alonso O.F., Huh P.W., Zhao W., Busto R., Ginsberg M.D. Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J. Neurotrauma 1999, 16:445-453.
4. Belayev L., Saul I., Huh P.W., Finotti N., Zhao W., Busto R., Ginsberg M.D. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Res. 1999, 845:107-111.
5. Belayev L., Saul I., Busto R., Danielyan K., Vigdorchik A., Khoutorova L., Ginsberg M. Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after intracortical hematoma in the rat. Stroke 2005, 36:326-331.
6. Boldt J. Use of albumin: an update. Br. J. Anaesth. 2010, 104:276-284.
7. Buisson A., Lesne S., Docagne F., Ali C., Nicole O., MacKenzie E.T., Vivien D. Transforming growth factor-beta and ischemic brain injury. Cell. Mol. Neurobiol. 2003, 23:539-550.
8. Buttram S.D., Wisniewski S.R., Jackson E.K., Adelson P.D., Feldman K., Bayir H., Berger R.P., Clark R.S., Kochanek P.M. Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J. Neurotrauma 2007, 24:1707-1717.
9. Cacheaux L.P., Ivens S., David Y., Lakhter A.J., Bar-Klein G., Shapira M., Heinemann U., Friedman A., Kaufer D. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J. Neurosci. 2009, 29:8927-8935.
10. Calvo C.F., Amigou E., Tence M., Yoshimura T., Glowinski J. Albumin stimulates monocyte chemotactic protein-1 expression in rat embryonic mixed brain cells. J. Neurosci. Res. 2005, 80:707-714.
11. Docagne F., Nicole O., Gabriel C., Fernandez-Monreal M., Lesne S., Ali C., Plawinski L., Carmeliet P., MacKenzie E.T., Buisson A., Vivien D. Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Mol. Cell. Neurosci. 2002, 21:634-644.
12. Ellis E.F., McKinney J.S., Willoughby K.A., Liang S., Povlishock J.T. A new model for rapid stretch-induced injury of cells in culture: characterization of the model using astrocytes. J. Neurotrauma 1995, 12:325-339.
13. Ginsberg M.D., Palesch Y.Y., Hill M.D. The ALIAS (Albumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem. Soc. Trans. 2006, 34:1323-1326.
14. Hooper C., Taylor D.L., Pocock J.M. Pure albumin is a potent trigger of calcium signalling and proliferation in microglia but not macrophages or astrocytes. J. Neurochem. 2005, 92:1363-1376.
15. Hooper C., Pinteaux-Jones F., Fry V.A., Sevastou I.G., Baker D., Heales S.J., Pocock J.M. Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood-brain barrier damage. J. Neurochem. 2009, 109:694-705.
16. Hu J., Castets F., Guevara J., Eldik L.V. S100B stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J. Biol. Chem. 1996, 271:2543-2547.
17. Hu J., Ferreira A., Eldik L.V. S100ß induces neuronal death through nitric oxide release from astrocytes. J. Neurochem. 1997, 69:2294-2301.
18. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., Laping N.J., Hill C.S. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002, 62:65-74.
19. Ivens S., Kaufer D., Flores L.P., Bechmann I., Zumsteg D., Tomkins O., Seiffert E., Heinemann U., Friedman A. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007, 130:535-547.
20. Jinnin M., Ihn H., Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol. Pharmacol. 2006, 69:597-607.
21. Jones N.C., Constantin D., Gibson C.L., Prior M.J., Morris P.G., Marsden C.A., Murphy S. A detrimental role for nitric oxide synthase-2 in the pathology resulting from acute cerebral injury. J. Neuropathol. Exp. Neurol. 2004, 63:708-720.
22. Kinoshita K., Chatzipanteli K., Vitarbo E., Truettner J.S., Alonso O.F., Dietrich W.D. Interleukin-1beta messenger ribonucleic acid and protein levels after fluid-percussion brain injury in rats: importance of injury severity and brain temperature. Neurosurgery 2002, 51:195-203.
23. Kozuka N., Kudo Y., Morita M. Multiple inhibitory pathways for lipopolysaccharide- and pro-inflammatory cytokine-induced nitric oxide production in cultured astrocytes. Neuroscience 2007, 144:911-919.
24. Ledeboer A., Breve J.J., Poole S., Tilders F.J., Van Dam A.M. Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia 2000, 30:134-142.
25. Louin G., Marchand-Verrecchia C., Palmier B., Plotkine M., Jafarian-Tehrani M. Selective inhibition of inducible nitric oxide synthase reduces neurological deficit but not cerebral edema following traumatic brain injury. Neuropharmacology 2006, 50:182-190.
26. Morganti-Kossmann M.C., Hans V.H., Lenzlinger P.M., Dubs R., Ludwig E., Trentz O., Kossmann T. TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood-brain barrier function. J. Neurotrauma 1999, 16:617-628.
27. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 2005, 26:349-354.
28. Nadal A., Fuentes E., McNaughton P.A. Glial cell responses to lipids bound to albumin in serum and plasma. Prog. Brain Res. 2001, 132:367-374.
29. Palesch Y., Hill M., Ryckborst R., Tamariz D., Ginsberg M. A dose-escalation and safety study of albumin therapy for acute ischemic atroke-II: Neurologic outcome and efficacy analysis. Stroke 2006, 37:2107-2114.
30. Palesch Y.Y., Hill M.D., Ryckborst K.J., Tamariz D., Ginsberg M.D. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: Neurologic outcome and efficacy analysis. Stroke 2006, 37:2107-2114.
31. Prehn J.H., Backhauss C., Krieglstein J. Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J. Cereb. Blood Flow Metab. 1993, 13:521-525.
32. Ralay Ranaivo H., Wainwright M.S. Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways. Brain Res. 2010, 1313:222-231.
33. Re D.B., Przedborski S. Fractalkine: moving from chemotaxis to neuroprotection. Nat. Neurosci. 2006, 9:859-861.
34. Ruocco A., Nicole O., Docagne F., Ali C., Chazalviel L., Komesli S., Yablonsky F., Roussel S., MacKenzie E.T., Vivien D., Buisson A. A transforming growth factor-[beta] antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J. Cereb. Blood Flow Metab. 1999, 19:1345-1353.
35. Myburgh J., Cooper D.J., Finfer S., Bellomo R., Norton R., Bishop N., Kai Lo S., Vallance S. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007, 357:874-884. SAFE Study Investigators.
36. Schmierer B., Hill C.S. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 2007, 8:970-982.
37. Si Q.S., Nakamura Y., Kataoka K. Albumin enhances superoxide production in cultured microglia. Glia 1997, 21:413-418.
38. Siddiqui S.S., Siddiqui Z.K., Malik A.B. Albumin endocytosis in endothelial cells induces TGF-beta receptor II signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L1016-L1026.
39. Sinz E.H., Kochanek P.M., Dixon C.E., Clark R.S., Carcillo J.A., Schiding J.K., Chen M., Wisniewski S.R., Carlos T.M., Williams D., DeKosky S.T., Watkins S.C., Marion D.W., Billiar T.R. Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice. J. Clin. Invest. 1999, 104:647-656.
40. Tabernero A., Velasco A., Granda B., Lavado E.M., Medina J.M. Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid. J. Biol. Chem. 2002, 277:4240-4246.
41. Takekawa M., Tatebayashi K., Itoh F., Adachi M., Imai K., Saito H. Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J. 2002, 21:6473-6482.
42. Tehranian R., Andell-Jonsson S., Beni S.M., Yatsiv I., Shohami E., Bartfai T., Lundkvist J., Iverfeldt K. Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J. Neurotrauma 2002, 19:939-951.
43. Thornton P., Pinteaux E., Allan S.M., Rothwell N.J. Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol. Cell. Neurosci. 2008, 37:135-142.
44. Unterberg A.W., Stover J., Kress B., Kiening K.L. Edema and brain trauma. Neuroscience 2004, 129:1021-1029.
45. Vecil G.G., Larsen P.H., Corley S.M., Herx L.M., Besson A., Goodyer C.G., Yong V.W. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J. Neurosci. Res. 2000, 61:212-224.
46. Wang Y., Moges H., Bharucha Y., Symes A. Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex. Exp. Neurol. 2007, 203:168-184.
47. Wu C.Y., Hsieh H.L., Jou M.J., Yang C.M. Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1beta-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J. Neurochem. 2004, 90:1477-1488.
48. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009, 19:128-139.
49. Zhao T.Z., Xia Y.Z., Li L., Li J., Zhu G., Chen S., Feng H., Lin J.K. Bovine serum albumin promotes IL-1beta and TNF-alpha secretion by N9 microglial cells. Neurol. Sci. 2009, 30:379-383.
50. Zujovic V., Benavides J., Vige X., Carter C., Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 2000, 29:305-315.